Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A1 | Q14973 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20238911 | 1.00 | SLC10A1 (1.00) | SLC10A1 | |
| SCHEMBL19901000 | 0.93 | SLC10A1 (1.00) | SLC10A1 | |
| SCHEMBL19900970 | 0.93 | SLC10A1 (1.00) | SLC10A1 | |
| SCHEMBL19900972 | 0.93 | SLC10A1 (1.00) | SLC10A1 | |
| SCHEMBL20253034 | 0.92 | SLC10A1 (0.87) | SLC10A1 | |
| SCHEMBL19900845 | 0.92 | SLC10A1 (1.00) | SLC10A1 | |
| SCHEMBL23369669 | 0.88 | SLC10A1 (0.87) | SLC10A1 | |
| SCHEMBL19900944 | 0.87 | SLC10A1 (1.00) | SLC10A1 | |
| SCHEMBL20253035 | 0.84 | SLC10A1 (0.84) | SLC10A1 | |
| SCHEMBL20252981 | 0.84 | SLC10A1 (0.74) | SLC10A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12161625-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| EP-3922634-B1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230270719-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-31 | — | — | US | disclosed |
| EP-3922634-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3922634-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20210251957-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20210251957-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2021-08-19 | — | — | US | disclosed |
| EP-3504212-B1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-3504212-B1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-10874640-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10874640-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200061024-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2020-02-27 | — | — | US | disclosed |
| US-20200061024-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2020-02-27 | — | — | US | disclosed |
| US-10328053-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-10328053-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180161307-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2018-06-14 | — | — | US | disclosed |
| US-20180161307-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2018-06-14 | — | — | US | disclosed |
| WO-2018039531-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200061024-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | SLC10A1 1948/4885 |
| US-12161625-B2 | Substituted pyrrolizine compounds and uses thereof | HMBS, DHFR, HCCS | SLC10A1 1948/4885 |
| US-10328053-B2 | Substituted pyrrolizine compounds and uses thereof | HMBS, DHFR, HCCS | SLC10A1 1948/4885 |
| US-20230270719-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | SLC10A1 1948/4885 |
| US-10874640-B2 | Substituted pyrrolizine compounds and uses thereof | HMBS, DHFR, HCCS | SLC10A1 1948/4885 |
| US-20180161307-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | SLC10A1 1948/4885 |
| US-20210251957-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | SLC10A1 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.